



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



E4CPG

Item No. 36667

CAS Registry No.: 170846-89-6
Formal Name: α -amino-4-carboxy- α -ethyl-benzeneacetic acid
Synonym: (R,S)- α -Ethyl-4-carboxyphenylglycine
MF: C₁₁H₁₃NO₄
FW: 223.2
Purity: \geq 98%
UV/Vis.: λ_{max} : 233 nm
Supplied as: A solid
Storage: -20°C
Stability: \geq 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

E4CPG is supplied as a solid. Aqueous solutions of E4CPG can be prepared by directly dissolving the solid in aqueous buffers. The solubility of E4CPG in PBS (pH 7.2) is approximately 0.1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

E4CPG is an antagonist of metabotropic glutamate receptor 1 (mGluR1) and mGluR2.¹ It is selective for mGluR1 and mGluR2 over mGluR6 at 1 mM. E4CPG (1 mM) inhibits L-glutamate-induced increases in inositol phosphate (InsP) levels in CHO cells expressing mGluR1 and prevents forskolin-induced decreases in cAMP levels in CHO cells expressing mGluR2. *In vivo*, intraplantar administration of E4CPG (1-10 nmol/paw) reduces glutamate-induced paw licking in a mouse model of nociceptive pain.²

References

1. Sekiyama, N., Hayashi, Y., Nakanishi, S., *et al.* Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. *Br. J. Pharmacol.* **117(7)**, 1493-1503 (1996).
2. Beirith, A., Santos, A.R.S., and Calixto, J.B. Mechanisms underlying the nociception and paw oedema caused by injection of glutamate into the mouse paw. *Brain Res.* **924(2)**, 219-228 (2002).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/21/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM